Hyeryeong Nam
Research Subjects
Hyeryeong Nam has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Bora Lee
Institute of Health and Environment, Seoul National University, Seoul, Korea
2 shared publications - Byung Kwan Park
Department of Surgery, Chung-Ang University College of Medicine, Seoul, Korea
1 shared publication - Eon Chul Han
Department of Surgery, Dongnam Institute of Radiological and Medical Sciences, Busan, Korea
1 shared publication - Hyun-Sook Kim
Division of Rheumatology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University School of Medicine, Seoul, South Korea
1 shared publication - In Ho Song
Asan Medical Center, Korea (South), Republic of
1 shared publication - Jeong-Ki Kim
Department of Surgery, Chung-Ang University College of Medicine, Seoul, Korea
1 shared publication
Latest Publications
- Open Access
- 30 September 2023
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 38 (3) , 482-489
The effects of oligomeric proanthocyanidins on hydroxychloroquine-induced retinopathy as revealed by nationwide medical claim data for South Korea
Although hydroxychloroquine (HCQ) is considered to be safe drug with anti-inflammatory, immunomodulatory, and antithrombotic effects,[1,2] rare cases of permanent visual impairment.[2,3] The prevalence of HCQ retinopathy is about 7.5% for more than five years, increasing after 20 years.[4] Oligomeric proanthocyanidins (OPCs) are antioxidants and rich in a grape seed extract.[5-7] The extract is effective in some patients with nonproliferative diabetic retinopathy.[8,9] The extract may protect retinal cells by inhibiting the oxidative stress-mediated apoptosis mediated by activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway in patients with diabetic retinopathy.[9] No study has explored whether the extract may protect against HCQ retinopathy.[10] We used nationwide medical claims data of the Korean Health Insurance Review and Assessment Service (HIRA) to find the effect of co-administration of OPC, as single product name Entelon®, on the incidence of HCQ retinopathy was investigated in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) who were receiving HCQ from 2007 to 2019 (Figure 1). Statistical analysis was performed using the SAS software (version 9.4; SAS Institute Inc., Seoul, Korea) and R statistical software (version 4.0.3; R Foundation for Statistical Computing, Vienna, Austria). We included 31,140 patients on HCQ in a no-OPC group and 7,785 in an OPC group after propensity score matching (Table 1a). The mean duration of HCQ use was 17.6±32.5 months and the mean cumulative dose 32.3±124.0 g (Table 1b). It was divided into three quantiles according to the HCQ durations and cumulative doses: low, medium, and high. By the duration of HCQ use, the cumulative incidence of retinopathy was 0 in the low and medium groups, but 3.92 (95% confidence interval [CI]: 3.52-4.35) in the high group (p
- 30 September 2023
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 38 (3) , 482-489
Open AccessThe effects of oligomeric proanthocyanidins on hydroxychloroquine-induced retinopathy as revealed by nationwide medical claim data for South Korea
Although hydroxychloroquine (HCQ) is considered to be safe drug with anti-inflammatory, immunomodulatory, and antithrombotic effects,[1,2] rare cases of permanent visual impairment.[2,3] The prevalence of HCQ retinopathy is about 7.5% for more than five years, increasing after 20 years.[4] Oligomeric proanthocyanidins (OPCs) are antioxidants and rich in a grape seed extract.[5-7] The extract is effective in some patients with nonproliferative diabetic retinopathy.[8,9] The extract may protect retinal cells by inhibiting the oxidative stress-mediated apoptosis mediated by activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway in patients with diabetic retinopathy.[9] No study has explored whether the extract may protect against HCQ retinopathy.[10] We used nationwide medical claims data of the Korean Health Insurance Review and Assessment Service (HIRA) to find the effect of co-administration of OPC, as single product name Entelon®, on the incidence of HCQ retinopathy was investigated in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) who were receiving HCQ from 2007 to 2019 (Figure 1). Statistical analysis was performed using the SAS software (version 9.4; SAS Institute Inc., Seoul, Korea) and R statistical software (version 4.0.3; R Foundation for Statistical Computing, Vienna, Austria). We included 31,140 patients on HCQ in a no-OPC group and 7,785 in an OPC group after propensity score matching (Table 1a). The mean duration of HCQ use was 17.6±32.5 months and the mean cumulative dose 32.3±124.0 g (Table 1b). It was divided into three quantiles according to the HCQ durations and cumulative doses: low, medium, and high. By the duration of HCQ use, the cumulative incidence of retinopathy was 0 in the low and medium groups, but 3.92 (95% confidence interval [CI]: 3.52-4.35) in the high group (p
- Open Access
- 1 January 2023
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 105 (5) , 281-289
Real-world survival after colorectal surgery for malignancy in Korean patients with chronic kidney disease: an analysis of Korean healthcare big data, 2002–2019
Song I, et al. Ann Surg Treat Res. 2023 Nov;105(5):281-289. https://doi.org/10.4174/astr.2023.105.5.281
- 1 January 2023
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 105 (5) , 281-289
Open AccessReal-world survival after colorectal surgery for malignancy in Korean patients with chronic kidney disease: an analysis of Korean healthcare big data, 2002–2019
Song I, et al. Ann Surg Treat Res. 2023 Nov;105(5):281-289. https://doi.org/10.4174/astr.2023.105.5.281